Table 1.
Clinical information and demographics of patients with cardiac implantable electronic device (CIED) infection.
| N = 219 | |
| Demographics | |
| Median age at study (max, min), years | 68 (58-77) |
| Male, n (%) | 161 (73.5) |
| Median duration of infection (max, min), days | 23 (10-37) |
| Underlying diseases | |
| Lung diseases, n (%) | 23 (10.5) |
| Renal diseases, n (%) | 27 (12.3) |
| Liver diseases, n (%) | 24 (11.0) |
| Diabetes mellitus, n (%) | 53 (24.2) |
| Hypertension, n (%) | 106 (48.4) |
| Types of infection | |
| Early post-implantation inflammation, n (%) | 32 (14.6) |
| Generator pocket infection, n (%) | 152 (69.4) |
| Constitutional symptoms, n (%) | 24 (11.0) |
| CIED-LI/IE∗, n (%) | 11 (5.0) |
| Positive culture results | |
| Blood, n (%) | 24 (11.0) |
| Pocket tissue, n (%) | 145 (66.2) |
| Treatment | |
| Re-implantation, n (%) | 137 (62.6) |
| Inappropriate empirical antimicrobial therapy | 68 (31.1) |
| Definitive antimicrobial therapy∗∗, n (%) | 79 (36.1) |
| Outcome | |
| Median length of stay (max, min), days | 15 (13-20) |
| In-hospital death, n (%) | 2 (0.9) |
∗CIED-LI/IE, cardiac implantable electronic device associated lead infection or infectious endocarditis; CoNS, coagulase-negative staphylococci. ∗∗Definitive antimicrobial therapy refers to the corrected therapy when microbiology results and antimicrobial susceptibility data were available.